Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $19,077.66 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 4,326 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $4.41, for a total transaction of $19,077.66. Following the completion of the sale, the chief executive officer now owns 220,119 shares of the company’s stock, valued at approximately $970,724.79. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, December 10th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.20, for a total transaction of $20,500.00.

Lexeo Therapeutics Stock Down 3.5 %

Shares of NASDAQ:LXEO traded down $0.14 on Friday, reaching $3.89. The company had a trading volume of 176,793 shares, compared to its average volume of 256,776. The stock has a market capitalization of $128.64 million, a P/E ratio of -1.23 and a beta of 2.99. The stock has a 50-day moving average price of $5.76 and a 200 day moving average price of $8.12. Lexeo Therapeutics, Inc. has a twelve month low of $3.84 and a twelve month high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright lifted their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Leerink Partners reduced their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Chardan Capital boosted their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Institutional Investors Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP grew its holdings in Lexeo Therapeutics by 0.8% during the fourth quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock valued at $5,650,000 after purchasing an additional 6,730 shares during the last quarter. Vestal Point Capital LP boosted its holdings in shares of Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after buying an additional 350,000 shares during the period. Point72 Asset Management L.P. grew its stake in Lexeo Therapeutics by 102.5% in the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after buying an additional 379,828 shares during the last quarter. Millennium Management LLC raised its holdings in Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company’s stock worth $934,000 after acquiring an additional 104,837 shares during the period. Finally, Janus Henderson Group PLC lifted its position in Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock worth $28,508,000 after acquiring an additional 576,059 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.